| Characteristic . | Total (n = 56) . |
|---|---|
| Number of eligible patients, median (range) | 73 (12–771) |
| Year of publication, median (range) | 2004 (1983–2019) |
| Mean follow-up period, median (range), days | 365 (56–2555) |
| Intervention categories evaluated, no. of trials/no. of analysed patients | |
| Bisphosphonates | 46/3508 |
| Vitamins/calcium | 15/585 |
| Teriparatide | 5/437 |
| Conjugated oestrogen | 1/13 |
| Raloxifene | 1/50 |
| Denosumab | 2/352 |
| Fluorides | 2/35 |
| Calcitonin | 3/62 |
| Thiazide | 1/11 |
| No treatment | 40/1426 |
| Outcomes analysed, no. of trials/no. of analysed patients | |
| Vertebral fractures | 53/6333 |
| Non-Vertebral fractures | 39/4880 |
| Patient characteristics | |
| Female, median (range), % | 68 (0–100) |
| Postmenopausal females, median (range), % | 46 (0–100) |
| GC users at baseline, median (range), % | 100 (0–100) |
| Mean age, median (range), years | 57 (31–72) |
| Mean cumulative GC dosage at baselinea, median (range), mg prednisone | 705 (0–55 100) |
| Characteristic . | Total (n = 56) . |
|---|---|
| Number of eligible patients, median (range) | 73 (12–771) |
| Year of publication, median (range) | 2004 (1983–2019) |
| Mean follow-up period, median (range), days | 365 (56–2555) |
| Intervention categories evaluated, no. of trials/no. of analysed patients | |
| Bisphosphonates | 46/3508 |
| Vitamins/calcium | 15/585 |
| Teriparatide | 5/437 |
| Conjugated oestrogen | 1/13 |
| Raloxifene | 1/50 |
| Denosumab | 2/352 |
| Fluorides | 2/35 |
| Calcitonin | 3/62 |
| Thiazide | 1/11 |
| No treatment | 40/1426 |
| Outcomes analysed, no. of trials/no. of analysed patients | |
| Vertebral fractures | 53/6333 |
| Non-Vertebral fractures | 39/4880 |
| Patient characteristics | |
| Female, median (range), % | 68 (0–100) |
| Postmenopausal females, median (range), % | 46 (0–100) |
| GC users at baseline, median (range), % | 100 (0–100) |
| Mean age, median (range), years | 57 (31–72) |
| Mean cumulative GC dosage at baselinea, median (range), mg prednisone | 705 (0–55 100) |
Cumulative GC dosages were converted to prednisone equivalent doses using the conversion table in the Oxford Handbook of Critical Care, 3rd edition [29].
| Characteristic . | Total (n = 56) . |
|---|---|
| Number of eligible patients, median (range) | 73 (12–771) |
| Year of publication, median (range) | 2004 (1983–2019) |
| Mean follow-up period, median (range), days | 365 (56–2555) |
| Intervention categories evaluated, no. of trials/no. of analysed patients | |
| Bisphosphonates | 46/3508 |
| Vitamins/calcium | 15/585 |
| Teriparatide | 5/437 |
| Conjugated oestrogen | 1/13 |
| Raloxifene | 1/50 |
| Denosumab | 2/352 |
| Fluorides | 2/35 |
| Calcitonin | 3/62 |
| Thiazide | 1/11 |
| No treatment | 40/1426 |
| Outcomes analysed, no. of trials/no. of analysed patients | |
| Vertebral fractures | 53/6333 |
| Non-Vertebral fractures | 39/4880 |
| Patient characteristics | |
| Female, median (range), % | 68 (0–100) |
| Postmenopausal females, median (range), % | 46 (0–100) |
| GC users at baseline, median (range), % | 100 (0–100) |
| Mean age, median (range), years | 57 (31–72) |
| Mean cumulative GC dosage at baselinea, median (range), mg prednisone | 705 (0–55 100) |
| Characteristic . | Total (n = 56) . |
|---|---|
| Number of eligible patients, median (range) | 73 (12–771) |
| Year of publication, median (range) | 2004 (1983–2019) |
| Mean follow-up period, median (range), days | 365 (56–2555) |
| Intervention categories evaluated, no. of trials/no. of analysed patients | |
| Bisphosphonates | 46/3508 |
| Vitamins/calcium | 15/585 |
| Teriparatide | 5/437 |
| Conjugated oestrogen | 1/13 |
| Raloxifene | 1/50 |
| Denosumab | 2/352 |
| Fluorides | 2/35 |
| Calcitonin | 3/62 |
| Thiazide | 1/11 |
| No treatment | 40/1426 |
| Outcomes analysed, no. of trials/no. of analysed patients | |
| Vertebral fractures | 53/6333 |
| Non-Vertebral fractures | 39/4880 |
| Patient characteristics | |
| Female, median (range), % | 68 (0–100) |
| Postmenopausal females, median (range), % | 46 (0–100) |
| GC users at baseline, median (range), % | 100 (0–100) |
| Mean age, median (range), years | 57 (31–72) |
| Mean cumulative GC dosage at baselinea, median (range), mg prednisone | 705 (0–55 100) |
Cumulative GC dosages were converted to prednisone equivalent doses using the conversion table in the Oxford Handbook of Critical Care, 3rd edition [29].
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
